MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down – Here’s What Happened

MoonLake Immunotherapeutics (NASDAQ:MLTX) gapped down prior to trading on Monday . The stock had previously closed at $18.26, but opened at $17.24. MoonLake Immunotherapeutics shares last traded at $17.1920, with a volume of 1,709,297 shares.

More MoonLake Immunotherapeutics News

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Positive Phase 3 psoriatic arthritis results: MoonLake said the IZAR-1 trial met all primary and secondary endpoints at Week 16 in biologic-naïve adults. The 60 mg dose produced an ACR50 response in 42.1% of patients, while ACR20 reached 66.5%; among patients with skin involvement, 61% achieved PASI90. The results support sonelokimab’s potential as a treatment for psoriatic arthritis. Reuters article
• Positive Sentiment: Solid financial position: MoonLake ended the second quarter with $537 million in cash, cash equivalents and short-term investments. Management expects its cash runway to extend into mid-2028, with up to $400 million still available under its debt facility. The company also expects to submit a hidradenitis suppurativa biologics license application by the end of September 2026.
• Positive Sentiment: Earnings exceeded expectations: The company reported a quarterly loss of $0.84 per share, better than the analyst consensus estimate for a $0.92 loss. However, MoonLake still reported a net loss of $61.8 million for the quarter. MoonLake quarterly press release
• Neutral Sentiment: Options activity increased: Investors purchased 2,707 call options, 142% above the average daily volume. This suggests increased bullish positioning or speculation, but options activity alone does not confirm a sustained move in the stock.
• Neutral Sentiment: Brokerage outlook remains cautious: Analysts collectively give MLTX an average “Hold” recommendation, indicating that strong clinical progress is already partly reflected in the valuation.
• Negative Sentiment: Insider selling is a concern: Company insiders made 20 reported sales and no purchases during the past six months, including substantial selling by the chief executive, chief scientific officer and chief financial officer. That activity may undermine investor confidence despite the positive trial results.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Leerink Partners raised their target price on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 12th. Needham & Company LLC raised their price target on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of MoonLake Immunotherapeutics in a research note on Monday, July 20th. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, MoonLake Immunotherapeutics currently has an average rating of “Hold” and a consensus price target of $24.21.

MoonLake Immunotherapeutics Price Performance

The company has a quick ratio of 8.60, a current ratio of 8.60 and a debt-to-equity ratio of 0.39. The company has a fifty day simple moving average of $19.05 and a two-hundred day simple moving average of $17.88. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -4.44 and a beta of 1.06.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Monday, August 10th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.08. On average, equities research analysts anticipate that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current fiscal year.

Insider Transactions at MoonLake Immunotherapeutics

In related news, insider Kristian Reich sold 50,000 shares of the company’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $20.02, for a total value of $1,001,000.00. Following the sale, the insider owned 2,714,746 shares of the company’s stock, valued at $54,349,214.92. The trade was a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the completion of the sale, the chief executive officer owned 2,774,893 shares of the company’s stock, valued at $55,553,357.86. The trade was a 2.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 344,800 shares of company stock worth $6,820,071. 10.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MLTX. Kestra Advisory Services LLC bought a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $26,000. Bank of America Corp DE increased its position in shares of MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after buying an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in MoonLake Immunotherapeutics by 115.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after acquiring an additional 3,166 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after purchasing an additional 1,069 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of MoonLake Immunotherapeutics during the 4th quarter valued at $47,000. 93.85% of the stock is owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.